Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells.

Servio H Ramirez, Raghava Potula, Shongshan Fan, Tess Eidem, Anil Papugani, Nancy Reichenbach, Holly Dykstra, Babette B Weksler, Ignacio A Romero, Pierre O Couraud, Yuri Persidsky
Author Information
  1. Servio H Ramirez: Department of Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

Abstract

Methamphetamine (METH), a potent stimulant with strong euphoric properties, has a high abuse liability and long-lasting neurotoxic effects. Recent studies in animal models have indicated that METH can induce impairment of the blood-brain barrier (BBB), thus suggesting that some of the neurotoxic effects resulting from METH abuse could be the outcome of barrier disruption. In this study, we provide evidence that METH alters BBB function through direct effects on endothelial cells and explore possible underlying mechanisms leading to endothelial injury. We report that METH increases BBB permeability in vivo, and exposure of primary human brain microvascular endothelial cells (BMVEC) to METH diminishes the tightness of BMVEC monolayers in a dose- and time-dependent manner by decreasing the expression of cell membrane-associated tight junction (TJ) proteins. These changes were accompanied by the enhanced production of reactive oxygen species, increased monocyte migration across METH-treated endothelial monolayers, and activation of myosin light chain kinase (MLCK) in BMVEC. Antioxidant treatment attenuated or completely reversed all tested aspects of METH-induced BBB dysfunction. Our data suggest that BBB injury is caused by METH-mediated oxidative stress, which activates MLCK and negatively affects the TJ complex. These observations provide a basis for antioxidant protection against brain endothelial injury caused by METH exposure.

References

  1. Brain Res. 2000 Jul 21;871(2):259-70 [PMID: 10899292]
  2. Brain Res. 2008 Apr 8;1203:133-48 [PMID: 18329007]
  3. J Forensic Sci. 1998 Jan;43(1):28-34 [PMID: 9456521]
  4. Exp Neurol. 2003 Jan;179(1):60-70 [PMID: 12504868]
  5. Am J Pathol. 1988 Jul;132(1):59-72 [PMID: 3394802]
  6. Synapse. 2007 Apr;61(4):216-20 [PMID: 17230548]
  7. Synapse. 2008 Mar;62(3):193-204 [PMID: 18081184]
  8. Synapse. 1994 Jul;17(3):203-9 [PMID: 7974204]
  9. Microcirculation. 2001 Dec;8(6):389-401 [PMID: 11781812]
  10. J Neuroimmunol. 2004 Dec;157(1-2):140-6 [PMID: 15579291]
  11. Pharmacol Biochem Behav. 1974 Jul-Aug;2(4):503-8 [PMID: 4423600]
  12. Brain Res. 2004 Jul 30;1016(1):90-5 [PMID: 15234256]
  13. J Pharmacol Exp Ther. 1985 Jun;233(3):539-44 [PMID: 2409267]
  14. Nat Rev Neurosci. 2007 Jan;8(1):33-44 [PMID: 17180161]
  15. Synapse. 2006 Dec 1;60(7):521-32 [PMID: 16952162]
  16. Microcirculation. 1998;5(2-3):197-210 [PMID: 9789260]
  17. J Neurosci Res. 2001 Nov 15;66(4):583-91 [PMID: 11746378]
  18. J Thromb Haemost. 2008 Sep;6(9):1453-60 [PMID: 18647230]
  19. J Biol Chem. 2006 Mar 31;281(13):8379-88 [PMID: 16439355]
  20. Synapse. 2005 Mar 1;55(3):137-47 [PMID: 15549691]
  21. Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H434-40 [PMID: 11123261]
  22. FASEB J. 2005 Nov;19(13):1872-4 [PMID: 16141364]
  23. Leukemia. 2007 Oct;21(10):2117-27 [PMID: 17690699]
  24. J Immunol. 2007 Jun 1;178(11):7334-43 [PMID: 17513784]
  25. Int J Neuropsychopharmacol. 2009 Jul;12(6):805-22 [PMID: 19149911]
  26. Nat Med. 1996 Jun;2(6):699-703 [PMID: 8640565]
  27. Brain Res. 2005 Jul 27;1051(1-2):72-80 [PMID: 16004973]
  28. Synapse. 2002 Jul;45(1):52-65 [PMID: 12112414]
  29. J Leukoc Biol. 2005 Dec;78(6):1223-32 [PMID: 16204625]
  30. J Neurosci. 2005 Jul 6;25(27):6449-59 [PMID: 16000635]
  31. Ann N Y Acad Sci. 2007 Dec;1122:260-75 [PMID: 18077579]
  32. J Neurosci. 2008 May 28;28(22):5756-61 [PMID: 18509037]
  33. AIDS Policy Law. 2005 Jul 1;20(13):5 [PMID: 16041854]
  34. Addiction. 2007 Apr;102 Suppl 1:49-60 [PMID: 17493053]
  35. Blood. 2006 Jun 15;107(12):4770-80 [PMID: 16478881]
  36. J Immunol. 2008 Feb 1;180(3):1854-65 [PMID: 18209083]
  37. Ann N Y Acad Sci. 2000 Sep;914:146-56 [PMID: 11085317]
  38. Sex Transm Infect. 2006 Apr;82(2):131-4 [PMID: 16581738]
  39. AAPS J. 2006 May 12;8(2):E337-47 [PMID: 16796384]
  40. Am J Pathol. 1999 Nov;155(5):1599-611 [PMID: 10550317]
  41. J Chem Neuroanat. 2009 Jan;37(1):18-32 [PMID: 18773954]
  42. J Cell Biol. 1995 Aug;130(3):613-27 [PMID: 7622562]
  43. Neurology. 2006 Oct 24;67(8):1486-9 [PMID: 17060582]
  44. IUBMB Life. 2004 May;56(5):249-55 [PMID: 15370888]
  45. Physiol Rev. 2006 Jan;86(1):279-367 [PMID: 16371600]
  46. J Appl Physiol (1985). 2001 Oct;91(4):1487-500 [PMID: 11568129]
  47. J Pharmacol Exp Ther. 1999 Dec;291(3):1220-6 [PMID: 10565845]
  48. Synapse. 2001 Feb;39(2):161-6 [PMID: 11180503]
  49. Clin Pharmacol Ther. 2003 Nov;74(5):475-86 [PMID: 14586388]
  50. J Neuroimmune Pharmacol. 2006 Sep;1(3):223-36 [PMID: 18040800]

Grants

  1. AA015913/NIAAA NIH HHS
  2. R01 MH065151/NIMH NIH HHS
  3. DA025566/NIDA NIH HHS
  4. R37 AA015913/NIAAA NIH HHS
  5. DA024979/NIDA NIH HHS
  6. R01 DA025566/NIDA NIH HHS
  7. R01 AA015913/NIAAA NIH HHS
  8. R21 DA024979/NIDA NIH HHS

MeSH Term

Animals
Antioxidants
Blood-Brain Barrier
Brain
Capillary Permeability
Cell Movement
Cells, Cultured
Central Nervous System Stimulants
Chromans
Endothelial Cells
Endothelium, Vascular
Humans
Male
Membrane Proteins
Methamphetamine
Mice
Mice, Inbred NOD
Monocytes
Oxidative Stress
Reactive Oxygen Species
Tight Junctions

Chemicals

Antioxidants
Central Nervous System Stimulants
Chromans
Membrane Proteins
Reactive Oxygen Species
Methamphetamine
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid

Word Cloud

Created with Highcharts 10.0.0METHendothelialBBBeffectsbarriercellsinjurybrainBMVECMethamphetamineabuseneurotoxicblood-brainprovidefunctionexposuremonolayersTJMLCKcausedoxidativestresspotentstimulantstrongeuphoricpropertieshighliabilitylong-lastingRecentstudiesanimalmodelsindicatedcaninduceimpairmentthussuggestingresultingoutcomedisruptionstudyevidencealtersdirectexplorepossibleunderlyingmechanismsleadingreportincreasespermeabilityvivoprimaryhumanmicrovasculardiminishestightnessdose-time-dependentmannerdecreasingexpressioncellmembrane-associatedtightjunctionproteinschangesaccompaniedenhancedproductionreactiveoxygenspeciesincreasedmonocytemigrationacrossMETH-treatedactivationmyosinlightchainkinaseAntioxidanttreatmentattenuatedcompletelyreversedtestedaspectsMETH-induceddysfunctiondatasuggestMETH-mediatedactivatesnegativelyaffectscomplexobservationsbasisantioxidantprotectiondisruptsinduction

Similar Articles

Cited By